PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Cabergoline - Hyperprolactinaemia
PAD Profile : Cabergoline - Hyperprolactinaemia Important
Keywords :
Hyperprolactinaemic disorders
Brand Names Include :
Dostinex
Important Information :
Initiation and supply of at least one month of treatment before transfer of prescribing to primary care. Monitoring remains the responsibility of secondary care in line with position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. https://pubmed.ncbi.nlm.nih.gov/30818417/
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
04 September 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed the following place in therapy for cabergoline and bromocriptine:
For the treatment of hyperprolactinaemic disorders
- BLUE traffic light classification for initiation by specialists for 1 month before transfer of prescribing responsibilities to primary care
- Cabergoline 1st line & Bromocriptine 2nd line
For the treatment of drug induced hyperprolactinaemia
- 1st line - select alternative medicine (to remove cause of drug-induced effect)
- Non-Formulary for cabergoline and bromocriptine
Suppression of lactation
- RED traffic light classification for cabergoline - as treatment should be part of obstetric care where necessary
- Non-Formulary for bromocriptine
Associated BNF Codes
06. Endocrine System
06.07.01. Bromocriptine and other dopaminergic drugs